The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial
Open accessAbstract
Background: In nonrandomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), fewer symptoms, and greater quality of life and exercise capacity in patients with heart failure (HF) and midrange or preserved ejection fraction (EF ≥40%). We conducted the first randomized sham-controlled trial to evaluate the IASD in HF with EF ≥40%. Methods: REDUCE LAP-HF I (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) was a phase 2, randomized, parallel-group, blinded multicenter trial in patients with New York Heart Association class III or ambulatory class IV HF, EF ≥40%, exercise PCWP ≥25 mm Hg, and PCWP-right atrial pressure gradient ≥5 mm Hg. Participants were randomized (1:1) to the IASD versus a sham procedure (femoral venous access with intracardiac echocardiography but no IASD placement). The participants and investigators assessing the participants during follow-up were blinded to treatment assignment. The primary effectiveness end point was exercise PCWP at 1 month. The primary safety end point was major adverse cardiac, cerebrovascular, and renal events at 1 month. PCWP during exercise was compared between treatment groups using a mixed-effects repeated measures model analysis of covariance that included data from all available stages of exercise. Results: A total of 94 patients were enrolled, of whom 44 met inclusion/exclusion criteria and were randomized to the IASD (n=22) and control (n=22) groups. Mean age was 70±9 years, and 50% were female. At 1 month, the IASD resulted in a greater reduction in PCWP compared with sham control ( P =0.028 accounting for all stages of exercise). Peak PCWP decreased by 3.5±6.4 mm Hg in the treatment group versus 0.5±5.0 mm Hg in the control group ( P =0.14). There were no peri-procedural or 1-month major adverse cardiac, cerebrovascular, and renal events in the IASD group and 1 event (worsening renal function) in the control group ( P =1.0). Conclusions: In patients with HF and EF ≥40%, IASD treatment reduces PCWP during exercise. Whether this mechanistic effect will translate into sustained improvements in symptoms and outcomes requires further evaluation. Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT02600234.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,191
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Self-citationZile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Nishimura, R. A., Sorajja, P., Lam, C. S. P., & Redfield, M. M. (2010) · Circulation: Heart Failure · doi:10.1161/circheartfailure.109.930701 · Cited by 1,118
The pathophysiology of heart failure with preserved ejection fraction
Borlaug, B. A. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.83 · Cited by 726
Melenovsky, V., Hwang, S.-J., Redfield, M. M., Zakeri, R., Lin, G., & Borlaug, B. A. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001667 · Cited by 530
Heart Failure with Preserved Ejection Fraction
Redfield, M. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1511175 · Cited by 510
Adamson, P. B., Abraham, W. T., Bourge, R. C., Costanzo, M. R., Hasan, A., Yadav, C., Henderson, J., Cowart, P., & Stevenson, L. W. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.113.001229 · Cited by 431
Freed, B. H., Daruwalla, V., Cheng, J. Y., Aguilar, F. G., Beussink, L., Choi, A., Klein, D. A., Dixon, D., Baldridge, A., Rasmussen-Torvik, L. J., et al. (2016) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.115.003754 · Cited by 395
Self-citation
Cited by
Evaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Cellular and molecular pathobiology of heart failure with preserved ejection fraction
Mishra, S., & Kass, D. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00480-6 · Cited by 417
Reddy, Y. N. V., Obokata, M., Verbrugge, F. H., Lin, G., & Borlaug, B. A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.009 · Cited by 407
Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355
Metadata
- Authors
- Feldman, T., Mauri, L., Kahwash, R., Litwin, S., Ricciardi, M. J., van der Harst, P., Penicka, M., Fail, P. S., Kaye, D. M., Petrie, M. C., Basuray, A., Hummel, S. L., Forde-McLean, R., Nielsen, C. D., Lilly, S., Massaro, J. M., Burkhoff, D., & Shah, S. J.
- Venue
- Circulation
- Published
- 2018-01-23
- Volume
- 137
- Issue
- 4
- Pages
- 364-375
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2769453207
- Cited by
- 269
- References
- 27
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. https://app.cochat.ai/papers/10.1161/circulationaha.117.032094
- The paper
- Feldman, T., Mauri, L., Kahwash, R., Litwin, S., Ricciardi, M. J., van der Harst, P., Penicka, M., Fail, P. S., Kaye, D. M., Petrie, M. C., Basuray, A., Hummel, S. L., Forde-McLean, R., Nielsen, C. D., Lilly, S., Massaro, J. M., Burkhoff, D., & Shah, S. J. (2018). Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. Circulation. https://doi.org/10.1161/circulationaha.117.032094
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.